Promedior and Stromedix Spot Fresh Approaches in Fibrosis
This article was originally published in Start Up
New approaches to treating fibrotic disorders have led to start-up financing for Promedior and Stromedix, two biotechs with early-stage in-licensed large molecule programs. To succeed where others have so-far failed the two newcomers will need innovative clinical strategies to accelerate their paths to proof-of-concept.
You may also be interested in...
$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.
Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.